Loading...
Loading...
BLRX| Name | Value |
|---|---|
| Revenues | 6.9M |
| Cost of Revenue | 1.5M |
| Gross Profit | 5.4M |
| Operating Expense | 10.2M |
| Operating I/L | -4.8M |
| Other Income/Expense | 4.1M |
| Interest Income | 0.6M |
| Pretax | -0.7M |
| Income Tax Expense | 5.4M |
| Net Income/Loss | -0.7M |
BioLineRx Ltd. is a clinical-stage biopharmaceutical development company specializing in oncology. The company's primary focus is on the development of Motixafortide, a peptide with applications in autologous stem cell mobilization, pancreatic cancer, metastatic pancreatic adenocarcinoma, acute respiratory distress syndrome, and solid tumors. Additionally, the company is developing AGI-134, an immuno-oncology agent for the treatment of solid tumors, and BL-5010, a pen-like applicator for non-surgical removal of skin lesions. BioLineRx has collaboration agreements with MSD and MD Anderson Cancer Center, as well as a licensing arrangement with Perrigo Company plc for the over-the-counter sale of BL-5010.
